Ziopharm Publishes on Positive Results of Phase 1 Glioblastoma Med Trial

Ziopharm Oncology, Inc. (‘Ziopharm’ or the ‘Company’) (Nasdaq: ZIOP), today announced the publication of its phase 1 trial of Controlled IL-12 in patients with recurrent glioma in the journal Science Translational Medicine.

The publication entitled, ‘Regulatable interleukin 12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial’ can be accessed at https://stm.sciencemag.org/.

While IL-12 is known as a potent immune activator that triggers T cells to target cancer, historic trials systemically infusing IL-12 protein have failed due to intolerable toxicity. In contrast, this study showed that a ligand-inducible gene switch regulates expression of IL-12 from the central nervous system, resulting in increased cytokine and T-cell activity within the tumor environment, while preserving a favorable safety profile.

https://www.marketscreener.com/ZIOPHARM-ONCOLOGY-INC-33865/news/Ziopharm-Oncology-Announces-Publication-of-Positive-Results-of-Phase-1-Monotherapy-Trial-of-Contro-29070774/